Protalix BioTherapeutics Q3 EPS $(0.02) Beats $(0.03) Estimate, Sales $14.248M Beat $11.6M Estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 80 percent increase over losses of $(0.1) per share from

Benzinga · 11/07/2019 14:46

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 80 percent increase over losses of $(0.1) per share from the same period last year. The company reported quarterly sales of $14.248 million which beat the analyst consensus estimate of $11.6 million by 22.83 percent. This is a 2.05K percent increase over sales of $663 thousand the same period last year.